ADMA: ADMA Biologics, Inc. Stock

by  •  • Comments Off on ADMA: ADMA Biologics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 4,805.72
Enterprise Value ($M) 4,806.62
Book Value ($M) 373.42
Book Value / Share 1.56
Price / Book 12.87
NCAV ($M) 214.66
NCAV / Share 0.90
Price / NCAV 22.39

Profitability (mra)
Return on Invested Capital (ROIC) 0.45
Return on Assets (ROA) 0.59
Return on Equity (ROE) 1.35

Liquidity (mrq)
Quick Ratio 3.36
Current Ratio 6.58

Balance Sheet (mrq) ($M)
Current Assets 351.81
Assets 510.57
Liabilities 137.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 426.45
Operating Income 138.98
Net Income 197.67
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 118.67
Cash from Investing -8.57
Cash from Financing -58.30

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G State Street Corp 4.80 -12.03
05-09 13G Invesco Ltd. 5.40 13.90
04-30 13G/A BlackRock, Inc. 15.10 -6.17
11-12 13G/A Vanguard Group Inc 7.77 0.00
09-23 13G Millennium Management Llc 0.60 -78.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-07 10-Q Item 1. Financial Statements.
2025-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-21 686,737 1,995,330 34.42
2025-05-20 681,618 2,118,456 32.18
2025-05-19 643,872 2,107,739 30.55
2025-05-16 549,480 1,933,652 28.42

(click for more detail)

Similar Companies
ACET – Adicet Bio, Inc. ACIU – AC Immune SA
ACRV – Acrivon Therapeutics, Inc. ALT – Altimmune, Inc.
ANIP – ANI Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io